Featured Pharma Online Editorial

1. Why Early Evaluation Of Process Parameters Matters In OSD Scale-Up 10/26/2026

   For oral solid dose (OSD) manufacturers, technology transfer often becomes an exercise in managing uncertainty. Differences in equipment, blending conditions, material properties, and tooling design can introduce challenges that may not become apparent until later-stage development or even commercial scale-up.

2. Printing A New Path To The Brain: 3D Buccal Nanofilms For CNS Lymphoma 10/19/2026

   Though methotrexate is the most effective therapeutic against primary central nervous system (CNS) lymphoma, it can cause toxicity issues at therapeutic concentrations. Aditi Suchitkumar Satoskar and her research team at Mercer University sought to look for alternatives, investigating a noninvasive approach that combines methotrexate-loaded bovine serum albumin nanoparticles, an RVG-derived brain-targeting peptide, and a 3D-printed buccal film.

3. Engineering Better ADCs, Part 2: Characterization, CMC, And More 10/1/2026

   Let's take a closer look at antigen selection and tumor biology, PK and PD, analytical characterization, CMC, toxicity, and more.

4. Engineering Better ADCs, Part 1: MoA, Conjugation Chemistry, And More 9/24/2026

   The field has evolved considerably in antibody–drug conjugate (ADC) science. In this first article of a two-part series, let's discuss how to engineer better ADCs, covering MoA, conjugation chemistry, and more.

5. 4 Ways To Build A Better CMC Tech Transfer 9/23/2026

   A technology transfer can falter long before a process reaches the plant. Gaps in process knowledge, mismatched equipment, and insufficient scale-up data can all undermine reproducibility, timelines, and cost.

6. Oral Combination Therapies: Navigating Development Complexities 9/10/2026

   We discuss how delivery strategy influences development decisions, learnings from advancing IHL-42X, and Latham's perspective on the future of patient-centric drug delivery.

7. CDMO Live Europe 2026: Partnerships For An Uncertain World 7/27/2026

   112 pages of executive insight from CDMO Live Europe 2026: tariffs, geopolitics, supply resilience, AI in manufacturing, and why strategic partnerships remain aspirational for most.

8. Resilience, Risk, And Relationships: CDMO Live Europe 2026 Report 7/27/2026

   Senior pharma leaders from Pfizer, Bayer, BioNTech and others debunk dual sourcing myths and reveal what separates strategic CDMO partnerships from transactional ones.

9. EMA's New Guideline For Synthetic Peptides: A More Explicit CMC Playbook For A Growing Therapeutic Class 6/23/2026

   The European Medicines Agency’s Guideline on the Development and Manufacture of Synthetic Peptides, adopted in Dec. 2025 and effective from June 1, 2026, is an important regulatory development for peptide manufacturers.

10. Can Molecular Glue Degraders Make The Undruggable Druggable? 6/12/2026

    Neomorph CEO Phil Chamberlain explains how molecular glue degraders could expand the druggable proteome and why the modality’s small-molecule profile may matter as much as its novel mechanism.